Kaposi Sarcoma Market By Treatment (Chemotherapy, Immunotherapy, Highly Active Antiretroviral Therapy (HAART), Radiation Therapy, Surgical Procedures) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Kaposi sarcoma is caused due to the infection of a virus called as Kaposi sarcoma associated herpes virus (KSHV). The disease prevalence is varied around the globe; there are four types of Kaposi sarcoma such as AIDS-KS, immunocompromised, classic or sporadic and endemic. Technological advancement in the drug delivery such as targeted immunotherapy and nanomedicines are utilized to facilitate the cytotoxic payload through the blood vessels in the Kaposi sarcoma tumors which usually develops from the cells that line the lymph or blood vessels.

For the purpose of this study, the global Kaposi sarcoma market is studied in terms of treatment types and geography. The drug classes studied in the report includes chemotherapy which is further categorized as (alkaloids and liposomal anthracyclines), immunotherapy, HAART, radiation therapy and surgical procedures. Market size estimates and forecast of these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The geographic segmentation of the global Kaposi sarcoma market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The regions are also further sub-segmented on the basis of major countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global Kaposi sarcoma market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global Kaposi sarcoma market. The key players profiled in this report are Aphios Corp, Cytori Therapeutics, Inc., Bristol Myers Squibb Company, CytRx Corporation, Eli Lilly and Co., GlaxoSmithKline plc, F.Hoffman La-Roche, Inc., Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc.

Kaposi Sarcoma Market

Choose License Type
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58687
Report Format:   PDF
Pages:   120
Rating:    4.3 (60)
Connect With Us
+1-408-641-3282
24/7 Research Support